Sugi Predict

Sugi Predict / Targets / STK17B

STK17B

Serine/threonine-protein kinase 17B · O94768 · STK17B on Sugi Atlas →

28,515 patent compounds predicted against STK17B, 20,807 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL147331 SCHEMBL147331 0.91 2/20
SCHEMBL141930 SCHEMBL141930 0.90 2/20
SCHEMBL142206 SCHEMBL142206 0.85 2/20
SCHEMBL144842 SCHEMBL144842 0.80 2/20
SCHEMBL144192 SCHEMBL144192 0.75 2/20
SCHEMBL144525 SCHEMBL144525 0.71 2/20
SCHEMBL146263 SCHEMBL146263 0.71 2/20
SCHEMBL141676 SCHEMBL141676 0.69 2/20
SCHEMBL145500 SCHEMBL145500 0.69 2/20
SCHEMBL144281 SCHEMBL144281 0.68 2/20
SCHEMBL141372 SCHEMBL141372 0.68 2/20
SCHEMBL145902 SCHEMBL145902 0.67 2/20
SCHEMBL146743 SCHEMBL146743 0.67 2/20
SCHEMBL144785 SCHEMBL144785 0.67 2/20
SCHEMBL147096 SCHEMBL147096 0.63 2/20
SCHEMBL144209 SCHEMBL144209 0.62 2/20
SCHEMBL144321 SCHEMBL144321 0.61 2/20
SCHEMBL146728 SCHEMBL146728 0.61 2/20
SCHEMBL147975 SCHEMBL147975 0.60 2/20
SCHEMBL144930 SCHEMBL144930 0.60 2/20

Clinical trials — most relevant to STK17B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. PHASE2ACTIVE_NOT_RECRUITING
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Effects of Vitamin D Supplementation on Muscle Protein Synthesis PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a STK17B binder may also engage these)

ProteinNameSimilarity
Q8BG48 — 1.000 Q8BG48 →
Q91XS8 — 1.000 Q91XS8 →
TSSK1B Testis-specific serine/threonine-protein kinase 1 0.985 landscape →
Q9GM70 — 0.984 Q9GM70 →
MELK Maternal embryonic leucine zipper kinase 0.978 landscape →
STK17A Serine/threonine-protein kinase 17A 0.978 landscape →
Q28GW8 — 0.977 Q28GW8 →
TSSK2 Testis-specific serine/threonine-protein kinase 2 0.977 landscape →
PLK2 Serine/threonine-protein kinase PLK2 0.976 landscape →
Q5R4L1 — 0.975 Q5R4L1 →
Q9Z265 — 0.975 Q9Z265 →
O54863 — 0.974 O54863 →
Q6DE87 — 0.974 Q6DE87 →
P53666 — 0.974 P53666 →
Q5HZ38 — 0.974 Q5HZ38 →
Q91821 — 0.973 Q91821 →
P53670 — 0.972 P53670 →
Q5SUV5 — 0.971 Q5SUV5 →
Q5E9J9 — 0.971 Q5E9J9 →
Q8VDF3 — 0.971 Q8VDF3 →
Q5ZK47 — 0.971 Q5ZK47 →
Q07192 — 0.971 Q07192 →
MYLK4 Myosin light chain kinase family member 4 0.971 landscape →
Q61846 — 0.971 Q61846 →
O54785 — 0.970 O54785 →
P09560 — 0.970 P09560 →
Q9WVC6 — 0.970 Q9WVC6 →
Q93V58 — 0.970 Q93V58 →
Q9YHZ5 — 0.969 Q9YHZ5 →
Q852Q2 — 0.969 Q852Q2 →